Fig. 4From: Nanocarrier cancer therapeutics with functional stimuli-responsive mechanismsPotential cell surface proteins and their complementary receptors for use in targeted-drug delivery applications. t-SNARE/v-SNARE target snap receptor/vesicle snap receptor; PS phosphatidylserine; C1q complement component 1q; SCARF-1 scavenger receptor class-F, member-1; Gp1b glycoprotein-Ib; TSP-2 thrombospondin-2; SIRPα signal regulatory protein α; CD cluster of differentiation; ICAM intercellular adhesion molecule; LFA-1 lymphocyte function-associated antigen-1; MAC-1 macrophage adhesion ligand-1; VLA very late antigen; PAMP pathogen associated molecular pattern; DAMP damage-associated molecular pattern; PD-1/PD-2 programmed cell death protein-1/programmed cell death protein-2; PD-L1/PD-L2 programmed death-ligand-1/programmed death-ligand-2; CTLA-4 cytotoxic t-lymphocyte-associated protein-4; TRAIL tumor necrosis factor-related apoptosis-inducing ligand; TNF tumor necrosis factor; B7-H6 B7 homolog 6; MIC MHC class I polypeptide-related sequence; H60 histocompatibility protein-60; NKp natural cytotoxicity triggering receptor; NKG natural killer cell granule protein; KIR killer-cell immunoglobulin-like receptor; LIR leukocyte immunoglobulin-like receptor; HMGβ1 high-mobility group protein β1; RAGE receptor for advanced glycation end products. Figure has been created using BiorenderBack to article page